Vanda Pharma Files 2025 Proxy Statement on Executive Pay
Ticker: VNDA · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1347178
| Field | Detail |
|---|---|
| Company | Vanda Pharmaceuticals Inc. (VNDA) |
| Form Type | DEF 14A |
| Filed Date | Apr 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
TL;DR
Vanda Pharma's 2025 proxy statement is out, detailing exec pay and equity awards for 2024.
AI Summary
Vanda Pharmaceuticals Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, outstanding awards, and changes in their fair value, as well as vesting dates for awards granted to its PEO (Principal Executive Officer) and other members. Specific dollar amounts for these awards are not detailed in the provided text snippet.
Why It Matters
This filing provides shareholders with crucial information regarding how Vanda Pharmaceuticals compensates its top executives, impacting corporate governance and investor decisions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of executive compensation and does not inherently present new financial risks.
Key Players & Entities
- Vanda Pharmaceuticals Inc. (company) — Filer of the DEF 14A
- 20250425 (date) — Filing date of the DEF 14A
- 20250605 (date) — Conformed period of report
- 2024-12-31 (date) — Fiscal year end for compensation data
- 2023-12-31 (date) — Previous fiscal year end for compensation data
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide shareholders with information regarding Vanda Pharmaceuticals Inc.'s executive compensation for the fiscal year ending December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 25, 2025.
What fiscal year does the compensation information in this filing primarily cover?
The compensation information in this filing primarily covers the fiscal year ending December 31, 2024.
What type of compensation details are mentioned in the filing?
The filing mentions details related to equity awards, including summary compensation tables, year-end fair value of outstanding and unvested awards, changes in fair value, and vesting dates for awards granted to PEO and other members.
What is Vanda Pharmaceuticals Inc.'s SIC code?
Vanda Pharmaceuticals Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding Vanda Pharmaceuticals Inc. (VNDA).